ALNY
Alnylam Pharmaceuticals, Inc. NASDAQ Listed Jun 1, 2004$295.81
Mkt Cap $39.5B
52w Low $245.96
20.0% of range
52w High $495.55
50d MA $317.73
200d MA $392.58
P/E (TTM)
123.9x
EV/EBITDA
92.8x
P/B
49.1x
Debt/Equity
1.6x
ROE
39.8%
P/FCF
111.9x
RSI (14)
—
ATR (14)
—
Beta
0.38
50d MA
$317.73
200d MA
$392.58
Avg Volume
1.2M
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
675 West Kendall Street · Cambridge, MA 02142 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 30, 2026 | BMO | 0.90 | 1.51 | +68.7% | 301.19 | +2.1% | +2.8% | -4.3% | +0.6% | +1.1% | +0.6% | — |
| Feb 12, 2026 | BMO | 1.16 | 0.82 | -29.3% | 322.28 | -2.4% | -4.3% | +1.9% | +5.8% | +0.0% | +2.0% | — |
| Oct 30, 2025 | BMO | 0.56 | 2.90 | +416.9% | 481.59 | -6.6% | -6.7% | +1.4% | -4.8% | -2.4% | +2.6% | — |
| Jul 31, 2025 | BMO | -0.54 | 0.32 | +158.9% | 339.80 | +3.0% | +15.4% | +2.4% | +4.4% | -0.2% | +2.2% | — |
| May 1, 2025 | BMO | -0.89 | -0.01 | +98.9% | 263.24 | -2.3% | -3.1% | +1.7% | +5.5% | -1.4% | +2.5% | — |
| Feb 13, 2025 | BMO | -0.62 | 0.06 | +109.7% | 265.96 | -2.8% | -0.4% | -3.2% | -2.5% | +0.2% | +0.2% | — |
| Oct 31, 2024 | BMO | -0.92 | -0.50 | +45.4% | 281.49 | -2.2% | -5.3% | +2.7% | -1.4% | -1.7% | +2.9% | — |
| Aug 1, 2024 | BMO | -1.07 | 0.56 | +152.3% | 237.46 | +5.3% | +13.1% | +1.3% | -2.6% | -0.9% | -0.9% | — |
| May 2, 2024 | BMO | -1.12 | -0.16 | +85.7% | 149.96 | +0.6% | +0.2% | +1.3% | -0.7% | +2.1% | -1.3% | — |
| Feb 15, 2024 | BMO | -1.20 | -1.10 | +8.3% | 164.15 | -8.6% | -10.2% | -0.3% | +1.8% | +3.4% | +5.2% | — |
| Nov 2, 2023 | BMO | -1.34 | 1.15 | +185.8% | 157.00 | +3.4% | +2.9% | +3.6% | -0.1% | +1.8% | -0.5% | — |
| Aug 3, 2023 | BMO | -1.72 | -2.21 | -28.5% | 187.01 | -2.6% | +1.7% | -2.4% | -0.7% | +0.3% | +0.8% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| May 1 | RBC Capital | Maintains | Outperform → Outperform | — | $309.49 | $308.76 | -0.2% | -4.3% | +0.6% | +1.1% | +0.6% | -2.3% |
| May 1 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $309.49 | $308.76 | -0.2% | -4.3% | +0.6% | +1.1% | +0.6% | -2.3% |
| Apr 13 | Truist | Maintains | Buy → Buy | — | $322.11 | $320.66 | -0.5% | +3.4% | +1.9% | -1.8% | -4.0% | -3.3% |
| Mar 25 | Chardan Capital | Maintains | Buy → Buy | — | $308.05 | $313.34 | +1.7% | +6.7% | -0.2% | -3.3% | -0.4% | +4.7% |
| Mar 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $308.05 | $313.34 | +1.7% | +6.7% | -0.2% | -3.3% | -0.4% | +4.7% |
| Mar 16 | Jefferies | Downgrade | Buy → Hold | — | $313.41 | $311.22 | -0.7% | +1.8% | +0.5% | -1.8% | -1.2% | +0.3% |
| Feb 18 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $332.61 | $328.86 | -1.1% | +0.0% | +2.0% | -0.9% | -2.0% | +1.1% |
| Feb 17 | Freedom Broker | Upgrade | Hold → Buy | — | $314.40 | $316.80 | +0.8% | +5.8% | +0.0% | +2.0% | -0.9% | -2.0% |
| Feb 17 | Canaccord Genuity | Maintains | Buy → Buy | — | $314.40 | $316.80 | +0.8% | +5.8% | +0.0% | +2.0% | -0.9% | -2.0% |
| Feb 17 | Freedom Capital Markets | Upgrade | Hold → Buy | — | $314.40 | $316.80 | +0.8% | +5.8% | +0.0% | +2.0% | -0.9% | -2.0% |
| Feb 13 | Chardan Capital | Maintains | Buy → Buy | — | $308.48 | $302.55 | -1.9% | +1.9% | +5.8% | +0.0% | +2.0% | -0.9% |
| Feb 12 | Needham | Maintains | Buy → Buy | — | $322.28 | $314.42 | -2.4% | -4.3% | +1.9% | +5.8% | +0.0% | +2.0% |
| Jan 30 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $346.79 | $343.10 | -1.1% | -2.5% | +0.3% | +3.7% | +0.0% | -5.9% |
| Jan 30 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $346.79 | $343.10 | -1.1% | -2.5% | +0.3% | +3.7% | +0.0% | -5.9% |
| Jan 30 | BofA Securities | Maintains | Buy → Buy | — | $346.79 | $343.10 | -1.1% | -2.5% | +0.3% | +3.7% | +0.0% | -5.9% |
| Jan 20 | RBC Capital | Maintains | Outperform → Outperform | — | $359.27 | $350.70 | -2.4% | -1.0% | +2.8% | +1.2% | -3.2% | +0.9% |
| Jan 20 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $359.27 | $350.70 | -2.4% | -1.0% | +2.8% | +1.2% | -3.2% | +0.9% |
| Jan 12 | BofA Securities | Maintains | Buy → Buy | — | $398.29 | $377.82 | -5.1% | -6.9% | -0.3% | -0.8% | -2.1% | +0.0% |
| Jan 12 | Needham | Maintains | Buy → Buy | — | $398.29 | $377.82 | -5.1% | -6.9% | -0.3% | -0.8% | -2.1% | +0.0% |
| Jan 8 | Truist | Maintains | Buy → Buy | — | $422.50 | $420.18 | -0.5% | -5.5% | -0.3% | -6.9% | -0.3% | -0.8% |
| Dec 15 | Leerink Partners | Maintains | Market Perform → Market Perform | — | $397.55 | $394.22 | -0.8% | -1.5% | -0.1% | +0.2% | +1.0% | +1.1% |
| Dec 11 | Stifel | Maintains | Buy → Buy | — | $404.46 | $403.36 | -0.3% | +2.0% | -3.7% | -1.5% | -0.1% | +0.2% |
| Nov 11 | Wells Fargo | Maintains | Equal Weight → Equal Weight | — | $441.70 | $443.53 | +0.4% | +2.3% | +0.2% | +0.3% | -1.1% | +2.5% |
| Nov 5 | Freedom Broker | Maintains | Buy → Buy | — | $423.47 | $422.11 | -0.3% | +2.6% | +1.4% | +0.5% | -0.2% | +2.3% |
| Oct 31 | Piper Sandler | Maintains | Overweight → Overweight | — | $449.56 | $449.00 | -0.1% | +1.4% | -4.8% | -2.4% | +2.6% | +1.4% |
| Oct 31 | Barclays | Maintains | Overweight → Overweight | — | $449.56 | $449.00 | -0.1% | +1.4% | -4.8% | -2.4% | +2.6% | +1.4% |
| Oct 30 | Jefferies | Maintains | Buy → Buy | — | $481.59 | $450.00 | -6.6% | -6.7% | +1.4% | -4.8% | -2.4% | +2.6% |
| Oct 17 | Truist | Maintains | Buy → Buy | — | $481.07 | $481.65 | +0.1% | +0.1% | +2.0% | -3.5% | -1.9% | -0.2% |
| Oct 13 | JP Morgan | Maintains | Overweight → Overweight | — | $460.46 | $456.13 | -0.9% | +1.0% | +0.9% | +0.2% | +2.3% | +0.1% |
| Oct 10 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $456.95 | $460.28 | +0.7% | +0.8% | +1.0% | +0.9% | +0.2% | +2.3% |
| Oct 6 | Stifel | Maintains | Buy → Buy | — | $456.35 | $458.69 | +0.5% | -1.0% | +1.7% | -1.9% | +1.4% | +0.8% |
| Oct 6 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $456.35 | $458.69 | +0.5% | -1.0% | +1.7% | -1.9% | +1.4% | +0.8% |
| Sep 19 | RBC Capital | Maintains | Outperform → Outperform | — | $452.17 | $457.68 | +1.2% | +0.3% | +1.2% | -1.0% | +0.9% | -1.9% |
| Sep 17 | BofA Securities | Maintains | Buy → Buy | — | $461.24 | $455.76 | -1.2% | -2.1% | +0.1% | +0.3% | +1.2% | -1.0% |
| Sep 16 | Goldman Sachs | Maintains | Buy → Buy | — | $461.14 | $465.14 | +0.9% | +0.0% | -2.1% | +0.1% | +0.3% | +1.2% |
| Sep 15 | Jefferies | Maintains | Buy → Buy | — | $465.89 | $464.80 | -0.2% | -1.0% | +0.0% | -2.1% | +0.1% | +0.3% |
| Sep 11 | Evercore ISI | Maintains | Outperform → Outperform | — | $469.31 | $474.34 | +1.1% | -0.2% | -0.6% | -1.0% | +0.0% | -2.1% |
| Sep 8 | BMO Capital | Maintains | Outperform → Outperform | — | $452.00 | $457.31 | +1.2% | +0.7% | +6.0% | -2.7% | -0.2% | -0.6% |
| Sep 2 | Citigroup | Maintains | Buy → Buy | — | $446.51 | $445.84 | -0.2% | +0.1% | +0.1% | +1.4% | -0.3% | +0.7% |
| Sep 2 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $446.51 | $445.84 | -0.2% | +0.1% | +0.1% | +1.4% | -0.3% | +0.7% |
| Aug 7 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $428.14 | $429.33 | +0.3% | +1.6% | +0.9% | -0.9% | -1.2% | +0.6% |
| Aug 6 | JP Morgan | Maintains | Overweight → Overweight | — | $418.91 | $418.76 | -0.0% | +2.2% | +1.6% | +0.9% | -0.9% | -1.2% |
| Aug 4 | Oppenheimer | Upgrade | Perform → Outperform | — | $401.80 | $406.65 | +1.2% | +4.4% | -0.2% | +2.2% | +1.6% | +0.9% |
| Aug 4 | Wolfe Research | Upgrade | Underperform → Peer Perform | — | $401.80 | $406.65 | +1.2% | +4.4% | -0.2% | +2.2% | +1.6% | +0.9% |
| Aug 1 | Piper Sandler | Maintains | Overweight → Overweight | — | $392.24 | $388.68 | -0.9% | +2.4% | +4.4% | -0.2% | +2.2% | +1.6% |
| Aug 1 | Chardan Capital | Maintains | Buy → Buy | — | $392.24 | $388.68 | -0.9% | +2.4% | +4.4% | -0.2% | +2.2% | +1.6% |
| Aug 1 | Morgan Stanley | Maintains | Equal Weight → Equal Weight | — | $392.24 | $388.68 | -0.9% | +2.4% | +4.4% | -0.2% | +2.2% | +1.6% |
| Aug 1 | UBS | Maintains | Buy → Buy | — | $392.24 | $388.68 | -0.9% | +2.4% | +4.4% | -0.2% | +2.2% | +1.6% |
| Aug 1 | Barclays | Maintains | Overweight → Overweight | — | $392.24 | $388.68 | -0.9% | +2.4% | +4.4% | -0.2% | +2.2% | +1.6% |
| Aug 1 | Raymond James | Maintains | Outperform → Outperform | — | $392.24 | $388.68 | -0.9% | +2.4% | +4.4% | -0.2% | +2.2% | +1.6% |
No insider trades available.
8-K
Alnylam Pharmaceuticals, Inc. -- 8-K Filing
Alnylam surpassed $1 billion in quarterly product revenues for the first time, driven by AMVUTTRA's launch for ATTR-CM, signaling strong commercial momentum for the RNAi therapeutics leader.
Apr 30
8-K
Unknown — 8-K Filing
Tenaya Therapeutics (TNYA) is advancing its cardiac disease pipeline with positive momentum, suggesting potential near-term clinical catalysts that could justify its clinical-stage valuation if development programs succeed.
Mar 11
8-K · 1.01
!! High
Tenaya Therapeutics, Inc. -- 8-K 1.01: Collaboration Agreement
Tenaya Therapeutics secured a $10 million collaboration agreement with Alnylam Pharmaceuticals to develop RNA-based therapeutics, providing funding and potential revenue expansion for the smaller biotech firm.
Mar 5
8-K · 5.02
!!! Very High
Alnylam Pharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Alnylam's board granted a special equity award to new CEO Yvonne Greenstreet as part of her executive compensation package, effective March 2, 2026.
Mar 4
8-K
Alnylam Pharmaceuticals, Inc. -- 8-K Filing
Alnylam Pharmaceuticals advanced its RNAi pipeline with three new Phase 3 studies, four proprietary CTAs, and a novel manufacturing platform, positioning the company for sustained growth in genetic disease treatment.
Feb 12
Data updated apr 24, 2026 5:26pm
· Source: massive.com